IRD Stock Summary and Trading Ideas (Opus Genetics | NASDAQ:IRD)

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. The company operates in one operating segment, which is the business of developing products related to vision performance and health.

Opus Genetics trades on the NASDAQ stock market under the symbol IRD.

As of July 14, 2026, IRD stock price declined to $3.56 with 954,080 million shares trading.

IRD has a beta of 0.62, meaning it tends to be less sensitive to market movements. IRD has a correlation of 0.01 to the broad based SPY ETF.

IRD has a market cap of $293.93 million. This is considered a Small Cap stock.

Last quarter Opus Genetics reported $2 million in Revenue and -$.75 earnings per share. This fell short of revenue expectation by $-750,736 and missed earnings estimates by -$.61.

The top ETF exchange traded funds that IRD belongs to (by Net Assets): VTI, IWM, VXF, IWO, IWC.

IRD has outperformed the market in the last year with a return of +215.0%, while the SPY ETF gained +21.8%. However, in the most recent history, IRD shares have underperformed the stock market with its stock returning -36.1% in the last 3 month period and -12.3% for the last 2 week period, while SPY has returned +9.9% and +1.5%, respectively.

IRD support price is $3.63 and resistance is $3.99 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IRD shares will trade within this expected range on the day.